ACTRN12605000236695尚未招募2 期
Phase II single centre study assessing the efficacy and safety of I-131 rituximab radioimmunotherapy of relapsed or refractory, CD 20 positive, diffuse large B cell lymphoma, with the primary objective tumour response.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- ot stated 至 ot stated（—）
- 性别
- All
入选标准
- •Histologically proven CD 20 positive diffuse large B cell lymphoma, previously treated with a chemotherapy regimen with or without rituximab in patients who have relapsed or are refractory; with a minimum life expectancy of 3 months.
排除标准
- •Pre-exisiting myelodysplasia.
研究者
相似试验
招募中
2 期
Evaluation of the efficacy of proton pump inhibitor for postoperative delirium after hepatobiliary and pancreatic surgeryJPRN-jRCTs041220114Sugiura Teiichi82
进行中（未招募）
不适用
A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with metastatic renal cell cancer (Bevacizumab with standard therapy in RCC) - Bevacizumab with standard therapy in RCCMetastatic renal cell cancerEUCTR2005-006161-13-DERoche Pharma AG
进行中（未招募）
1 期
Study assessing if a chemotherapy drug called Cabazitaxel is effective in Patients with certain type of breast cancer (HER2 negative) that has spread to brain that is un treatable.Her-2 negative breast cancer with brain metastasesMedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000542-35-GBThe Clatterbridge Cancer Centre NHS Foundation Trust19
已完成
2 期
Efficacy of cabazitaxel in patients with HER2-negative metastatic breast cancerPatients with HER2-negative metastatic breast cancer and having unresectable brain metastases.Malignant neoplasm of breastCancerISRCTN79877830The Clatterbridge Cancer Centre NHS Foundation Trust (UK)19
尚未招募
2 期
Biomarcer-2 :Biomarker informed optimal management of advanced RAS wild type colorectal cancerAdvanced RAS Wild type right sided Colorectal cancerCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12623000874617Australasian Gastrointestinal Trials Group29